Abstract: The present invention is directed to RNA monomers comprising O-acetal levulinyl protecting groups at the 2? and/or the 5?-hydroxy functionalities of the ribose moiety. Said monomers may be incorporated into oligoribonucleotides or RNA polynucleotides. Furthermore, the invention is directed to methods for the synthesis of said RNA monomers, oligoribonucleotides and RNA polynucleotides, as well as methods for their deprotection and methods for the use of said compounds and compositions comprising said compounds. In particular, such compounds and compositions comprising them are used in methods for light-directed synthesis of RNA microarrays.
Type:
Grant
Filed:
September 4, 2009
Date of Patent:
February 2, 2016
Assignees:
The Royal Institute for the Advancement of Learning/McGill University, Wisconsin Alumni Research Foundation
Inventors:
Masad Damha, Jeremy Lackey, Debbie Mitra, Marvin Wickens, Franco Cerrina, Saima A. Akhtar, Mark Somoza
Abstract: The present invention relates to the use of active substance combinations for controlling animal pests, for example, from the chinch bug family (Lygaeidae), as well as animal pests that has shown resistance to pyrethroids.
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
January 26, 2016
Assignee:
BAYER CROPSCIENCE LP
Inventors:
Jeffrey A. Michel, Kenneth A. Kukorowski
Abstract: A composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifluoromethyl group, and one or more phenylpyrazole compounds selected from group (A) consisting of fipronil and ethiprole is provided by the present invention, and this composition has an excellent pesticidal effect.
Abstract: The invention relates to (among other things) oligomer-aryloxy-substituted propanamine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated aryloxy-substituted propanamine compounds.
Type:
Grant
Filed:
April 13, 2009
Date of Patent:
January 12, 2016
Assignee:
NEKTAR THERAPEUTICS
Inventors:
Jennifer Riggs-Sauthier, Franco J. Duarte
Abstract: Disclosed are encapsulating methods and encapsulated products. A payload material may be encapsulated within a wall material. The carrier material and payload material form a combination that is at least substantially solid at room temperature but that is sufficiently fluid at milling temperature to permit milling and subsequent encapsulation. The payload material may be, for instance, a bitter tasting material. In some embodiments, the microcapsules will serve a taste masking function. In other embodiments, the microcapsules may be used where a slow release of the payload material is desired.
Abstract: The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.
Type:
Grant
Filed:
April 4, 2011
Date of Patent:
November 24, 2015
Assignee:
MERCK SHARP & DOHME CORP.
Inventors:
ZhiQiang Yang, Philippe G. Nantermet, Constantine Kreatsoulas, Keith P. Moore, Evan Foster Shalen
Abstract: The invention relates to (among other things) oligomer-amino acid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated amino acid compounds.
Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
Abstract: The present invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm2 or more, which is obtained by granulating a powder containing an active ingredient with a binding solution containing mannitol and corn-derived pregelatinized starch, mixing the resulting granules with at least one kind of a disintegrant selected from cornstarch, hydroxypropylstarch, carmellose and crospovidone, and compression molding the mixture.
Type:
Grant
Filed:
June 10, 2009
Date of Patent:
September 1, 2015
Assignee:
Sumitomo Dainippon Pharma Co., Ltd.
Inventors:
Toru Fukushima, Takashi Shimizu, Teruko Yoshida
Abstract: The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof.
Type:
Grant
Filed:
June 3, 2009
Date of Patent:
August 18, 2015
Assignee:
Janssen Pharmaceutica NV
Inventors:
Joannes Theodorus Maria Linders, Peter Walter Maria Roevens, Brian Joel Hrupka
Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
Type:
Grant
Filed:
January 9, 2012
Date of Patent:
August 11, 2015
Assignees:
ZINFANDEL PHARMACEUTICALS, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITED
Abstract: The present invention relates to a method of preventing or treating a disease caused by infection by a eukaryotic pathogen, wherein the method comprises administering an effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of a eukaryotic pathogen's adenylyl cyclase that do not substantially modulate an adenylyl cyclase of the subject. The invention also provides methods for culturing eukaryotic pathogens and methods for inducing the pathogenic state in vitro.
Type:
Grant
Filed:
January 11, 2008
Date of Patent:
August 4, 2015
Assignee:
CORNELL RESEARCH FOUNDATION, INC.
Inventors:
Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi
Abstract: 1,4 naphthoquinones derivatives, of formula (I) wherein A is selected from the following rings: their preparation and their application as antimalarial agents
Type:
Grant
Filed:
March 25, 2009
Date of Patent:
July 28, 2015
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), REPRECHT-KARLS-UNIVERSITAT HEIDELBERG
Inventors:
Elisabeth Davioud-Charvet, Tobias Muller, Holger Bauer, R. Heiner Schirmer
Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.
Abstract: Provision of a stable ?-lipoic acid. A method for producing ?-lipoic acid nanoparticles, the method comprising the steps of: preparing an aqueous dispersion liquid containing ?-lipoic acid and a nonionic surfactant; adding a divalent metal salt into the aqueous dispersion liquid, wherein the divalent metal salt is a divalent metal halide, a divalent metal acetate or a divalent metal gluconate; and adding an alkali metal carbonate or an alkali metal phosphate into the aqueous dispersion liquid which has been added with the divalent metal salt, thereby forming ?-lipoic acid nanoparticles.
Type:
Grant
Filed:
December 12, 2008
Date of Patent:
July 14, 2015
Assignees:
Ezaki Glico Co., Ltd., Nanoegg Research Laboratories, Inc.
Abstract: The present invention is directed to methods of treating a patient for a disease or condition associated with adipogenesis or insulin resistance by administering a retinaldehyde compound to the patient or a compound that increases endogenous retinaldehyde levels by inhibiting the enzyme retinaldehyde dehydrogenase 1.
Abstract: Compounds of formula (I): in free or salt or solvate form, where X, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
Type:
Grant
Filed:
April 27, 2009
Date of Patent:
July 14, 2015
Assignee:
NOVARTIS AG
Inventors:
Catherine Leblanc, Cathy Ritchie, Duncan Shaw, Nikolaus Johannes Stiefl
Abstract: There are disclosed are compounds of the formula: wherein R1 and R2 are as disclosed herein, which are eIF4E inhibitors useful in the treatment of cancers. Also disclosed are compositions comprising the compounds, as well as methods of treating cancer using the compounds.
Abstract: The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.
Type:
Grant
Filed:
April 18, 2011
Date of Patent:
July 7, 2015
Assignee:
MERCK SHARP & DOHME CORP.
Inventors:
Philippe G. Nantermet, Zhi-Qiang Yang, Constantine Kreatsoulas, Abbas M. Walji, Hong Zhu
Abstract: The present invention relates to the use of specific fungicidal active substances, alone or in combination, for controlling mycoses in plants of the palm family and to a method for using said specific fungicidal active substances for controlling said mycoses in the field of plant protection and the protection of materials.
Type:
Grant
Filed:
April 14, 2011
Date of Patent:
June 9, 2015
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Dirk Ebbinghaus, Kerstin Hesse, Marie-Claire Grosjean-Cournoyer, David Chamberlin